LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Tarsus Launches "Your Mitey Problem," the First Direct-to-Consumer TV Campaign for XDEMVY (Lotilaner Ophthalmic Solution) 0.25%
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer analyst Francois Brisebois maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference